Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form

Blome, Christine; Stülpnagel, C C von; Augustin, Matthias; Mrowietz, Ulrich; Reich, Kristian; Muehlan, Holger; Kirsten, Natalia; Langenbruch, Anna; Sorbe, C.; Klein, Toni Maria

doi:10.1111/bjd.21593

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…F I G U R E 2 Key recommendations for implementing a people-centred approach to psoriasis treatment practice. 66,[98][99][100][101][102] CLCI, Cumulative Life Course Impairment; DLQI, Dermatology Life Quality Index; EBM, evidenced-based medicine; EQ-5D, EuroQoL 5 Dimensions; PBI-10, Patient Benefit Index-10; PCHC, people-centred healthcare; PHQ-2, Patient Health Questionnaire-2; PRO, patient-reported outcome; WHO-5, WHO-Five Well-being Index.…”

Section: Shortcomings Of Current Standard Measures Of Qol In Psoriasismentioning

confidence: 99%

Implementing well‐being in the management of psoriasis: An expert recommendation

Sommer,

Mrowietz,

Gaarn Du Jardin

et al. 2023

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

Psoriasis causes detriment in a person's physical, mental and social health which impairs their quality of life (QoL). However, the current psoriasis management may not adequately address all relevant health domains.Since the goal of healthcare is to restore or maintain health, health outcomes should include all areas of the patient's overall health. Life‐satisfaction, QoL and patient wellbeing are essential to a comprehensive approach to the disease. With the inclusion of more people‐centred policies, care of patients with psoriasis should evolve toward a holistic and integrated assessment of the disease impact, including subjective measures of wellbeing in order to encompass all aspects of health.The main objective of this expert review is to give the concept of wellbeing a place as an entity within the holistic therapeutic approach for patients with psoriasis. Identifying and defining common goals beyond the skin with the patient and testing them throughout the course of treatment will benefit and enhance treatment success. We propose a series of recommendations for application in clinical practice, providing tangible clinical guidance for implementing wellbeing in the management of psoriasis. Among the recommendations are the need to initially listen to the patient, to know their level of empowerment or what they want to achieve, their preferences in decision making, the evaluation of not only the physical but also the emotional impact of the disease (wellbeing), the definition of the aspects that can generate a cumulative deterioration of the disease throughout life, and a continuous assessment of the patient's preferences with the opinion of the expert clinician and the integration of the knowledge of external clinical evidence.

show abstract

Section: Shortcomings Of Current Standard Measures Of Qol In Psoriasismentioning

confidence: 99%

Implementing well‐being in the management of psoriasis: An expert recommendation

Sommer,

Mrowietz,

Gaarn Du Jardin

et al. 2023

Acad Dermatol Venereol

Self Cite

View full text Add to dashboard Cite

show abstract

Goals and benefits in topical treatment for psoriasis: development and pilot validation of a patient-reported outcomes tool, the Patient Benefit Index for Topical Treatment (PBI-TOP)

Blome,

Hülswitt,

Meineke

et al. 2024

British Journal of Dermatology

View full text Add to dashboard Cite

Background Topical agents are an essential component of psoriasis therapy. Objectives To develop a new version of the patient-reported Patient Benefit Index assessing the importance and achievement of treatment goals in topical psoriasis therapy in adult patients (PBI-TOP). Methods In semi-structured interviews, focus groups, and free-text questionnaires, patients reported their needs in topical treatment. Based on qualitative content analysis, items were developed by a consensus group and were refined in cognitive debriefing interviews. A pilot validation assessed the PBI-TOP and convergent criteria (Dermatology Life Quality Index, DLQI; Psoriasis Area and Severity Index, PASI; affected Body Surface Area, BSA). Results Thirty patients (26–72 years, mean 47, 60% male) reported various treatment goals relating to the themes ‘effectiveness’ and ‘characteristics of the preparation’. Twenty patients took part in cognitive debriefings (22–84 years, mean 50.6, 50% male). N = 154 patients participated in the pilot validation (18–85 years, mean 46.9, 63.6% male). An importance-weighted total score on overall effectiveness and three subscales based on exploratory factor analysis were defined: effectiveness on symptoms; effectiveness on quality of life; characteristics of the preparation. All scores showed excellent internal consistency (alpha > 0.9). The global effectiveness score correlated significantly with DLQI (r = -0.41), PASI (r = -0.32), and BSA (r = -0.22). The effectiveness subscales correlated significantly with DLQI (r = -0.41; -0.32) and PASI (r = -0.27; -0.33). The score on characteristics of the preparation correlated significantly with the DLQI (r = -0.34). Conclusion The PBI-TOP showed good feasibility and favourable psychometric characteristics in this pilot validation.

show abstract

How can we better address patients’ needs in topical psoriasis treatment?

Zhang,

Schuttelaar

2024

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form

Cited by 3 publications

References 8 publications

Implementing well‐being in the management of psoriasis: An expert recommendation

Implementing well‐being in the management of psoriasis: An expert recommendation

Goals and benefits in topical treatment for psoriasis: development and pilot validation of a patient-reported outcomes tool, the Patient Benefit Index for Topical Treatment (PBI-TOP)

How can we better address patients’ needs in topical psoriasis treatment?

Contact Info

Product

Resources

About